Yeh, Eric J. http://orcid.org/0000-0002-9357-9626
Rajkovic-Hooley, Olivera http://orcid.org/0000-0002-3299-1537
Silvey, Mark http://orcid.org/0000-0002-9096-3139
Ambler, William S. http://orcid.org/0000-0002-4305-0783
Milligan, Gary http://orcid.org/0000-0002-1427-3339
Pinedo-Villanueva, Rafael http://orcid.org/0000-0002-4723-5128
Harvey, Nicholas C.
Moayyeri, Alireza
Funding for this research was provided by:
UCB Pharma
Amgen
Article History
Received: 30 January 2023
Accepted: 6 June 2023
First Online: 19 June 2023
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.
: Informed consent was obtained from all individual participants included in the study.
: Eric Yeh is an employee of Amgen and holds Amgen stock. Olivera Rajkovic-Hooley, Mark Silvey, Will S Ambler and Gary Milligan are employees of Adelphi Real World, which received payment from UCB Pharma and Amgen Inc as part of this research. Rafael Pinedo-Villanueva has received research funding from Amgen, Fondation privée des HUG (Geneva, Switzerland), the International Osteoporosis Foundation, Kyowa Kirin Services, the Royal Osteoporosis Society, and the UK NIHR in addition to lecture fees and/or consulting honoraria from Amgen, Astellas, the International Osteoporosis Foundation, Mereo Biopharma, and UCB Pharma. Nicholas C Harvey has received honoraria, personal, consultancy and lecture fees from Alliance for Better Bone Health, AMGEN, Consilient Healthcare, Eli Lilly, Internis Pharma, Kyowa Kirin, MSD, Servier, Shire, and UCB Pharma. Alireza Moayyeri is an employee and stockholder of UCB Pharma.